Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Boehringer Ingelheim acquired Nerio Therapeutics for $1.3bn in July as part of its cancer push, gaining a preclinical immune ...

German pharma giant claims Granules India’s ANDA infringes five patents I Combination therapy Jentadueto among Boehringer’s ...

The solution combines three medications delivering the broadest spectrum of protection against internal and external ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...

The original version of this story misstated the source of Engelhorn's inheritance. She is an heir to the Boehringer Mannheim ...

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...

Paola Casarosa, Board of Managing Directors, Head of Innovation Unit at Boehringer Ingelheim, said: “Zongertinib’s efficacy and tolerability profile has the potential to become part of the future ...

Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...